Compare PSIX & CRVS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | PSIX | CRVS |
|---|---|---|
| Founded | 1985 | 2014 |
| Country | United States | United States |
| Employees | 1000 | N/A |
| Industry | Industrial Machinery/Components | Biotechnology: Pharmaceutical Preparations |
| Sector | Industrials | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 929.2M | 1.1B |
| IPO Year | N/A | 2016 |
| Metric | PSIX | CRVS |
|---|---|---|
| Price | $32.58 | $14.89 |
| Analyst Decision | Strong Buy | Strong Buy |
| Analyst Count | 2 | 6 |
| Target Price | ★ $99.95 | $30.17 |
| AVG Volume (30 Days) | 380.1K | ★ 1.4M |
| Earning Date | 05-11-2026 | 05-07-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ 48.04 |
| EPS | ★ N/A | N/A |
| Revenue | N/A | N/A |
| Revenue This Year | $24.73 | N/A |
| Revenue Next Year | $16.20 | N/A |
| P/E Ratio | $17.20 | ★ N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $31.90 | $3.96 |
| 52 Week High | $121.47 | $26.95 |
| Indicator | PSIX | CRVS |
|---|---|---|
| Relative Strength Index (RSI) | 32.01 | 57.88 |
| Support Level | N/A | $14.24 |
| Resistance Level | $43.75 | $16.85 |
| Average True Range (ATR) | 1.99 | 0.81 |
| MACD | -0.02 | 0.12 |
| Stochastic Oscillator | 8.71 | 60.08 |
Power Solutions International Inc is an America-based company that manufactures, distributes, and services power systems that run on nondiesel fuels, including natural gas, propane, and gasoline. The company's products are designed to meet emission standards imposed by environmental regulatory bodies like the Environmental Protection Agency. Its products are distributed to a wide range of industrial original equipment manufacturers that supply equipment to sectors including power generation, oil and gas, material handling, airport ground support, agricultural, turf, construction and irrigation. The company generates majority of its sales from United States, and also has its presence in North America (outside of United States), Pacific Rim, Europe and Others.
Corvus Pharmaceuticals Inc is a clinical stage biopharmaceutical company developing product candidates that precisely target proteins that are critical to immune cell maturation and function. It believes its proprietary product candidates have broad potential to address immune mediated diseases, inflammatory diseases and cancers. Its product candidate, soquelitinib, is designed to bind specifically to a protein, interleukin 2 inducible T cell kinase (ITK), involved in T cell activation, T cell receptor signaling and T cell differentiation and function. The company operates in one primary business activity and operate as one reportable segment.